Trump Administration Revokes Major Loan Guarantee for Sunnova Energy

Published 2 days agoNOVA

Trump Administration Revokes Major Loan Guarantee for Sunnova Energy

In a significant shift in policy, the Trump administration has annulled a $2.92 billion partial loan guarantee that was previously awarded to Sunnova Energy, a prominent residential solar panel installer in the U.S. Reuters reported that the Department of Energy (DOE) has formally 'de-obligated' the guarantee, releasing the federal government from its financial commitment linked to Project Hestia.

Project Hestia, which was announced under President Biden in April 2023, aimed to install nearly 100,000 rooftop solar systems to assist low-income households. It represented the DOE's largest solar financing effort at the time. However, Sunnova's financial struggles became evident earlier this year when the company issued a 'going concern' warning in March 2025, casting serious doubt on its ability to sustain operations over the coming twelve months.

Despite these challenges, Sunnova has been exploring other funding options, such as issuing $371 million in bonds backed by the now-revoked loan guarantee, which aren't part of its current restructuring plans. This cancellation by the Trump administration aligns with a broader reassessment of clean energy financing by the DOE, in favor of policies that prioritize the oil and gas industries.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Gilead Sciences' Trodelvy and Keytruda Combo Shows Promise in Breast Cancer Treatment

Gilead Sciences' Trodelvy and Keytruda Combo Shows Promise in Breast Cancer Treatment

5 minutes agoGILD

Gilead Sciences' Trodelvy, when paired with Merck's Keytruda, has exhibited notable success in combating advanced triple-negative breast cancer (TNBC). Results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial revealed a significant improvement in treatment outcomes. This combination therapy demonstrated a median progression-free survival of 11.2 months, markedly better than the 7.8 months for patients receiving standard chemotherapy alongside Keytruda, according to Reuters. The trial also highlighted an improved median response duration for the Trodelvy-Keytruda treatment, clocking in at 16.5 months, compared to just 9.2 months in the chemotherapy group. Reuters reported that the safety profile of the combination therapy remained consistent with the known effects of each drug individually, and no new safety issues emerged. These findings suggest the Trodelvy-Keytruda regimen could soon become a preferred option for treating advanced TNBC, offering a potential new standard of care for this particularly aggressive cancer subtype. However, ongoing evaluation and broader adoption are necessary to confirm its effectiveness on a wider scale.

DoorDash Boosts Global Presence with Major Acquisitions

DoorDash Boosts Global Presence with Major Acquisitions

20 minutes agoDASH

DoorDash, led by CEO Tony Xu, has taken a significant step to expand its global reach with the announced acquisitions of UK-based Deliveroo and hospitality software firm SevenRooms. In May 2025, DoorDash agreed to purchase Deliveroo for £2.9 billion, equivalent to $3.9 billion, in a deal that offers a 29% premium over Deliveroo's previous share price. As reported by AP News, this acquisition bolsters DoorDash's presence in Europe, Asia, and the Middle East. In addition to the Deliveroo deal, DoorDash is set to acquire SevenRooms for $1.2 billion. This acquisition aims to enhance DoorDash's restaurant services and solidify its standing in the food delivery market. By integrating SevenRooms' software capabilities, DoorDash seeks to offer more comprehensive solutions to restaurants and improve its service offerings. These strategic moves mark DoorDash's most significant acquisitions since its purchase of Wolt Enterprises in 2022, according to Reuters. The company's aggressive expansion into new markets aims to fortify its position against competitors such as Just Eat and Uber Eats. By broadening its international footprint, DoorDash continues to consolidate the food delivery industry under Tony Xu's leadership.

Moderna's New COVID-19 Vaccine Wins FDA Approval

Moderna's New COVID-19 Vaccine Wins FDA Approval

50 minutes agoMRNA

Moderna has received FDA approval for its latest COVID-19 vaccine, mNEXSPIKE, specifically for adults aged 65 and older, as well as individuals 12 to 64 with at least one underlying health condition. This development marks a significant step for Moderna, as it aims to address the changing landscape of vaccine demand. Reuters reported that this approval follows the FDA's updated guidelines, which now require testing against inert placebos for healthier, younger adults. The mNEXSPIKE vaccine presents several logistical advantages, notably its capability to be stored in a refrigerator, which improves shelf life and simplifies distribution. Clinical trials have shown that the vaccine not only matches but exceeds the efficacy of Moderna's original Spikevax vaccine. Moderna plans to make mNEXSPIKE available during the 2025-2026 respiratory virus season, coinciding with a time when demand for their earlier vaccines has waned. Amid this approval, the vaccine environment remains dynamic. The CDC, under Robert F. Kennedy Jr., continues to assert that COVID-19 vaccines are optional for children, underscoring the varied regulatory approaches to vaccination. Meanwhile, Moderna has also decided to pull its application for a combination flu-COVID vaccine, opting to await more data to support its efficacy.

China's Automotive Price War Escalates Amid BYD and Tesla Cuts

China's Automotive Price War Escalates Amid BYD and Tesla Cuts

8 hours agoTSLA

China's automotive industry is currently witnessing an intense price war, primarily driven by heavyweights Tesla and BYD. In a bid to stimulate sales, BYD has aggressively reduced prices on over 20 models, including the Seagull EV, now marked at 55,800 yuan ($7,780). Tesla has followed suit by slashing up to 70,000 yuan ($9,600) off its Model S and Model X, intensifying competition and placing increased pressure on premium automakers, the South China Morning Post reported. The aggressive discounting strategies have triggered concerns over the industry's financial health and led to notable market repercussions. According to reports, Chinese EV stocks have suffered substantial declines, with BYD's shares falling nearly 9% and competitors like Geely, Li Auto, and Xpeng recording losses of 7%, 5%, and 4%, respectively. This situation has also stirred tensions between major players, notably BYD and Great Wall Motor, highlighting the industry's strained dynamics. In response to these developments, the Chinese government has stepped in, urging an end to the cut-throat pricing to protect the sector's stability. Reuters noted that the Ministry of Industry and Information Technology plans to work with law enforcement to address unfair competition practices, aiming for a more sustainable and stable automotive market environment. These actions reflect the broader challenges and regulatory scrutiny faced by the industry amidst the ongoing price wars.